2022-000565-40: A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG Estudio en fase II, aleatorizado, abierto, de 12 semanas de duración, para evaluar la farmacodinámica, seguridad, tolerabilidad y farmacocinética de dosis múltiples de GLM101 administrado por vía intravenosa a participantes adultos con PMM2-CDG |
|
|
| Not yet recruiting | 2 | 6 | Europe | GML 101, GLM 101, Solution for infusion | Glycomine, Inc, Glycomine, Inc | PMM2-CDG PMM2-CDG, genetic metabolic disorder trastorno metabólico genético, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
